ONCAlert | Upfront Therapy for mRCC

Gastric Cancer VIEW MORE >>

The approval of TAS-102 has been backed by the European Medicines Agency's Committee for Medicinal Products for Human Use for the treatment of adult patients with metastatic gastric cancer, including adenocarcinoma of the gastroesophageal junction, in those previously treated with at least 2 prior systemic therapy regimens for advanced disease.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.